Pharmaceutical composition for preventing cancers through targeting mitochondria and application of pharmaceutical composition

A technology of composition and mitochondria, which is applied in the direction of drug combination, medical preparations containing active ingredients, antineoplastic drugs, etc., can solve the problems such as the mechanism of action is not yet clear, and achieve the effect of preventing low physiological function, preventing effect and improving energy

Active Publication Date: 2020-05-08
SHANGHAI TENTH PEOPLES HOSPITAL
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, reports on the specific effects of these drugs are mainly limited to antioxidative effects or compensating mitochondrial respiratory chain function, and their deeper mechanism of action has not yet been clarified.
At the same time, there are few studies on the synergy between d

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing cancers through targeting mitochondria and application of pharmaceutical composition
  • Pharmaceutical composition for preventing cancers through targeting mitochondria and application of pharmaceutical composition
  • Pharmaceutical composition for preventing cancers through targeting mitochondria and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Based on the production of 2000 capsules, weigh raw materials PRE 12.5g, MLT 1.5g, Se 0.1g, LA 75g, GSH300g, Q10 75g, Bifidobacteria 5×10 9 CFU, according to the conventional capsule production process, add the remaining amount of carrier corn starch, crystalline cellulose, lactose, magnesium stearate, polyvinylpyrrolidone, mix and granulate, fill in gelatin hard capsules, and prepare 2000 capsules, each Capsule content 0.5g.

Embodiment 2

[0053] Based on the production of 2000 tablets, take raw materials PRE 12.5g, MLT 1.25g, Se 0.05g, LA 75g, GSH112.5g, Q10 37.5g, Bifidobacteria 2.5×10 9 CFU, according to the conventional tablet production process, mixed with the rest of corn starch, crystalline cellulose, lactose, carboxymethyl cellulose and magnesium stearate, added polyvinylpyrrolidone aqueous solution as a binder for granulation, and finally added talc powder As a lubricant, tableting was prepared to obtain 2000 tablets of 0.25 g each.

Embodiment 3

[0054] Example 3: Effect of pharmaceutical composition on tumor volume.

[0055] The experimental animals were C57BL / 6J mice, 4-week-old males, randomly divided into tumor-bearing control group, DDP group and several drug groups, with 3 mice in each group. The experimental period is 4 weeks.

[0056] The drug group is further divided into a single drug group and a drug composition group.

[0057] Among them, the single drug component was divided into 5 groups: PRE group, MLT group, LA group, GSH group and Q10 group.

[0058] The pharmaceutical composition group includes Se+PRE group, Se+MLT group, PRE+MLT group, Q10+GSH group, Q10+LA group, GSH+LA group, Se+PRE+MLT group, Q10+LA+GSH group There are totally 9 groups with the pharmaceutical composition group (7 Drugs) of the present invention.

[0059] The experiment was administered 10 days in advance, and each drug group mixed its single drug or drug composition in the feed and fed it to the mice until the end of the 4-week...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition for preventing cancers through targeting mitochondria. The pharmaceutical composition contains active ingredients and pharmaceutically-acceptableor food-acceptable carriers, wherein the active ingredients are as follows: dehydroepiandrosterone or pregnenolone, melatonin, selenium, lipoic acid, reduced glutathione, coenzyme Q10 and bifidobacterium. The pharmaceutical composition serves as a mitochondria energy drug, and multiple-target-point remediation of mitochondrial functions is guaranteed through overall construction of organism mitochondria, so that an intervention effect is achieved before or during the generation of cancer cells, the growth of the cancer cells is inhibited, and the cancers are prevented.

Description

technical field [0001] The invention relates to a pharmaceutical composition. The pharmaceutical composition of the invention can improve the mitochondrial function of the body, inhibit the generation of cancer cells caused by the reduction of the mitochondrial activity of the body, and prevent the occurrence of cancer. Background technique [0002] As one of the essential organelles in the body, mitochondria are ancient, important, complex and delicate organelles in eukaryotic cells. Mitochondria's ancient symbiotic origin, unique double-membrane cristae structure, and semi-autonomous self-replication ability endow mitochondria with important and diverse functions. For the body, mitochondria are the final place for eukaryotic cells to carry out biological oxidation and energy synthesis, and are the fundamental source of energy consumed by human activities. [0003] With further in-depth research on mitochondria, it is found that mitochondria are not only the "energy power ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/06A61P35/00A61K31/5685A61K31/4045A61K33/04A61K31/385A61K31/122A61K35/745A61K31/57
CPCA61K31/122A61K31/385A61K31/4045A61K31/5685A61K31/57A61K33/04A61K35/745A61K38/06A61P35/00A61K2300/00
Inventor 范理宏
Owner SHANGHAI TENTH PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap